In humans and other mammals, female cells carry two X-chromosomes, whereas male cells carry a single X and Y-chromosome. To achieve an equal expression level of X-linked genes in both sexes, a dosage compensation mechanism evolved, which results in transcriptional silencing of one X-chromosome in females. X chromosome inactivation (XCI) is random with respect to the parental origin of the X, occurs early during embryonic development, and is then stably maintained through a near infinite number of cell divisions. As a result of this, every female individual consists of a mosaic of two different cell populations, in which either the maternally or paternally derived X-chromosome is inactivated. As the X-chromosome harbors more than a thousand genes, of which many are implicated in human disease when mutated, this mosaicism has important disease implications.
X-CHROMOSOME INACTIVATION AND THE NEED FOR DOSAGE COMPENSATION
Both sexes contain an equal number of autosomal chromosomes, and a balanced dosage of X-linked genes is needed to accomplish functional cell physiology. In heterogametic species, the evolution of a single gene-rich X and gene-pore Y-chromosome in males results in potential dosage problems, as in males only a single Xchromosome is responsive for the same functions as two X-chromosomes in females. Many genes act in dosedependent manners, and therefore during the attrition of the proto-Y, monosomy of the proto-X-chromosome in males is believed to be compensated by an up-regulation of gene transcription from the developing Xchromosome, thereby restoring the equilibrium between autosomal and X-linked genes 1 . For females, this upregulation of X-linked gene transcription would further disrupt the desired equilibrium, as the presence of two, highly transcribed, X-chromosomes would disrupt equal gene dosage between the autosomes and sexchromosomes. To prevent this potential problem, in placental mammals such as humans, dosage compensation of X-linked genes between both sexes is achieved by inactivation of one of the two X-chromosomes in females, a process called X-chromosome inactivation (XCI) 1, 2 . XCI occurs during early female development, and results in heterochromatinization and silencing of the X-chromosome, which is maintained during subsequent cell divisions throughout life 3 . XCI leads to mono-allelic expression of most X-linked genes, with the exception of genes located in the pseudo-autosomal regions (PARs) and a number of other genes escaping from inactivation 4 .
These latter genes often have X-degenerate counterparts on the Y-chromosome, which also carries a PAR homologous to that of the X-chromosome. Since expression of X-encoded genes from this chromosome and the single X-chromosome in male cells is two-fold up-regulated compared to autosomes, the proper dosage of Xencoded genes is restored, thereby complying to Ohno's hypothesis 1, 5 .
As a consequence of the stable XCI maintenance, adult females are a mosaic of two different cell populations, in which either the maternal or paternal X-chromosome is inactivated. As many X-linked genes can contribute to human disease, this mosaicism is an important modifier of X-linked genetic disorders. Whereas male patients suffering from X-linked mutations are usually strongly affected, the phenotype of X-linked disorders in females is highly variable. The origin of this variability is caused by the XCI-process. Here, we will first discuss the latest insights into the regulation of the XCI-process, followed by a detailed discussion on the mechanisms contributing to variability of X-linked disorders in females.
Lessons from mouse ES cells for the regulation of XCI
In mice, XCI occurs in two different forms 6, 7 . Around the 2-to 8-cell stage, imprinted-XCI is initiated, in which the paternal X-chromosome is silenced. Imprinted-XCI is maintained in extra-embryonic tissues, but is reversed in the epiblast which will form the embryo, around day 4.25 (E4.25) of development. Then, a second wave of random-XCI, in which either the maternal or paternal X-chromosome is silenced, is initiated around E5.5 postimplantation, and this process is finalized approximately a day later. As mouse embryonic stem (ES) cells can be derived from the preimplantation epiblast, when both X-chromosomes are active, these cells can be used as an ex vivo model to study the XCI-process, as they undergo XCI upon differentiation 7, 8 .
Early studies in mouse and man have shown that a region on the X-chromosome, called the Xinactivation-center (XIC) is crucial for XCI to occur (Figure 1 ). Within the XIC-region, several genes have been localized which execute XCI. The most important gene is the X-inactive-specific-transcript (Xist in mouse, XIST in human), which encodes a non-coding RNA molecule [9] [10] [11] . This RNA becomes upregulated upon differentiation, is able to spread along the future inactive X-chromosome (Xi) and attracts chromatin modifying enzymes which establish XCI-silencing. A major focus on XCI-research has been the regulation of Xistexpression, and the question why always one X-chromosome is kept active per diploid genome. In mouse, XCI appears to be directed by a stochastic mechanism, where XCI-initiation is regulated by autosomally-encoded XCI-inhibitors, and X-linked XCI-activators 12 . As the latter are X-linked, they will be expressed in a higher dose in females compared to males, and can explain female-specific XCI-initiation. One such factor identified is Rnf12, which is located in close proximity to Xist [13] [14] [15] . RNF12 is an E3 ubiquitin ligase, which is able to target the ES cell factor and XCI-inhibitor REX1 for proteasomal degradation 16 . REX1 represses Xist directly but also stimulates expression of Tsix 16, 17 , which is an antisense transcript being transcribed throughout Xist, thereby inhibiting Xist-expression 18 . Hence, when Rnf12 becomes upregulated in female cells upon development, the break on Xist-expression is released, allowing female-specific Xist-expression. The latter is only possible when the Xist locus is located in a transcription prone environment, and as such there is an important role for the cisacting elements and genes surrounding the Xist-locus, including the cis-acting genes Jpx, Ftx and the Xpr region 19 . Also Tsix is regulated by a wide range of genes and elements located in its vicinity 20 , and together, these elements and genes located on both sides of Xist and Tsix might play an important role in determining which of the two X-chromosomes is more likely to become inactivated. Whereas the role of Rnf12 in the regulation of XCI in ES cells and in imprinted-XCI is well established [13] [14] [15] , its role in random-XCI in the mouse epiblast has remained a matter of debate 21 . So far, most studies have focused on mouse XCI, and therefore much less is known about the timing and factors directing human XCI. In human, TSIX is only partially conserved and does not overlap with XIST, and a role for RNF12 in human XCI has yet to be confirmed. Unfortunately, most human ES cells are in a post-XCI state which prevents investigations on XCI-initiation 22 . Few studies have addressed XCI-initiation in human embryos, with conflicting results, where one study found XCI-initiation in cleavage stage embryos comparable to the mouse 23 , whereas another study found XCI-initiation on both Xchromosomes at the blastocyst stage without silencing, which only occurs at later stages on a single Xchromosome 24 . A recent study has used in vitro culture of human embryos on decidualized endometrial stromal cells up to E8 of development, and found H3K27me3 on one X-chromosome in cells from trophectoderm and hypoblast indicative for XCI, but not in epiblast cells, arguing that XCI during human development might be regulated in a lineage specific fashion 25 . Also, it has remained a matter of debate whether imprinted-XCI can occur in human 26, 27 . Future research is needed to address many of these open questions.
MENDELIAN INHERITANCE OF X-LINKED TRAITS
Many decades ago, prior to the discovery of chromosomes and genes, it was noticed that several diseases, including color-blindness and hemophilia, were occurring almost only in males (reviewed in 28 ). It was noticed that these diseases were not transmitted from affected males to their sons, but that healthy daughters could give birth to sons who were again affected. Although at that time no explanation existed for this way of inheritance, it is now clear that this pattern of inheritance is typical for X-linked traits. The first X-linked trait, the white-eye characteristic, was discovered more than a century ago in Drosophila 29 . It was found that when a white-eye male fly was bred to a red-eye female, all offspring had red eyes. When this offspring was inbred with each other, a quarter of all offspring had again white eyes, and these white-eyed flies were all males. From this it was concluded that the trait for eye color in flies must be sex-linked, and that the red eyes trait in flies is dominant, whereas the white-eye characteristic is recessive 29 . This and other work in flies was extended to the X and Ysystem in human, leading to the first rules on X-linked inheritance. These rules can still be found in nowadays textbooks of genetics, and state that a character is dominant when it is expressed in a heterozygote, and recessive when not. X-linked recessive diseases almost exclusively affect males (hemizygous for the X-chromosome), and rarely affect homozygous recessive females. Affected males cannot transmit their trait to their sons, rendering male-to-male transmission impossible. Transmission however can occur through their daughters, since all daughters will be obligate carriers, but since they are most likely heterozygous, they will not express the trait.
These female carriers however can transmit the trait to their offspring, resulting in 50% of the daughters being a carrier, and 50% of the sons being affected. Therefore, affected males can transmit an X-linked recessive disease to 50% of their grandsons through their obligate carrier daughters. In X-linked dominant diseases, an excess of affected females exists in pedigrees of the disease, and again male-to-male transmission is impossible. However, all daughters of an affected male will have the disease, since the dominant trait will be expressed in the heterozygous females. Since both sexes in the offspring of these females have an equal chance of obtaining the X-chromosome carrying the mutant allele, half off the offspring of both sexes will be affected.
Although these rules are strait and in concordance with the inheritance of sex-linked traits in Drosophila, several important exceptions apply to humans. Dosage compensation in Drosophila is achieved by up-regulation of gene expression from the single X-chromosome in males 30 . In human, however, one of the two X-chromosomes in females is silenced, and since XCI is basically random in every cell, females are a mosaic of cells in which either the maternal or paternal X-chromosome is inactivated 2 . In Drosophila, a recessive trait on the X-chromosome is really behaving recessively, since both X-chromosomes in a cell are active and thus being expressed. However, in women, this is not the case. If both X-chromosomes have an equal chance of being inactivated, in half of the cells the recessive allele will be inactivated and hence not expressed, whereas in the other half the recessive allele will be present on the active X-chromosome (Xa). Thus even a recessive trait will be uniquely expressed in half of the cells of women, therefore making it dominant at the cellular level, and should thus result in a phenotype similar to that in hemizygous males. Indeed, far more female carriers of an Xlinked disease present with clinical symptoms 31, 32 , which cannot be explained by simplified rules of dominant and recessive X-linked inheritance as obtained in the Drosophila model, deduced at a time that knowledge on differences between human and Drosophila dosage compensation was lacking 33 . In agreement with this, a systematic review of 32 X-linked diseases has shown that, as expected based on the X-linked pattern of inheritance, the severity and penetrance, which is the frequency with which a genotype manifest itself in a given phenotype, are higher in males than in females carrying an X-linked disease mutation, whereas the severity and penetrance are highly variable in heterozygous females, varying from high, to intermediate and low between different disorders, but also in females being affected with the same disease 33 . Thus apparently, for X-linked diseases, classifications as recessive and dominant are misleading, and can better be described as X-linked 33 .
X-CHROMOSOME INACTIVATION MOSAICISM AND SKEWING AS

MODIFIERS OF X-LINKED HUMAN DISEASE IN FEMALES
In complex organisms like humans, different cell types have to work together to obtain normal physiology. As a XCI consequence, and the clonal propagation of the inactivated Xi state, women are a mosaic of two cell populations, with either the maternally or the paternally inherited X-chromosome being inactivated 3 Interestingly, not always does cell communication results in amelioration of an X-linked disorder and in some cases it might even worsen the phenotype in heterozygous females ( Figure 2C ). This is the case for EFNB1 gene mutations which cause craniofrontonasal syndrome (OMIM: 304110) 40 . The absence of functional ephrin B1 protein, a signaling molecule involved in many developmental processes, results in premature closure of the coronal suture (craniosynostosis), and thus aberrant skull development, only in females. Males with mutations in EFNB1 do not develop these skull deformations, because other redundant signaling molecules are able to replace the function of ephrin B1. In case of heterozygous females, where XCI has resulted in a mixture of cells which are either positive or negative for ephrin B1, such a redundant signaling pathway is disrupted by a mechanism called cellular interference 41 . A similar mechanism has been proposed in an affected boy, carrying a mosaic of a supernumerary small ring X-chromosome harboring EFNB1 42 , and in affected males harboring somatic mosaicism with an EFNB1 mutant cell line 43 .
Although XCI in principal results in two different cell populations, and this can have profound effects on the manifestation of X-linked diseases in heterozygous females, another layer of complexity is added by the fact that the ratio of the two cell lines, with either the maternal or paternal X-chromosome being inactivated, is not always 50:50. In fact, studies have shown that in large populations of healthy women, the ratio between both cell types follows a bell-shaped distribution, with a mean of 50:50 and extremes approaching 100:0 or 0:100 44 .
Just by chance, a proportion of women will have a deviation from the 50:50 ratio and this deviation is called XCI-skewing (Figure 2D, E) . How can skewing be explained? Several factors might contribute, and most likely one of the most important factors will be the presence of a limited amount of cells at the moment that XCI is initiated. Even when every cell has a 50% chance of inactivating the one or the other X-chromosome, when the starting pool of cells is small, just by chance the majority of cells might choose to inactivate for example the paternal X-chromosome. Although it is not exactly known how many cells are present at the moment that XCI is initiated in the human embryo, it is estimated that the number of cells which commence to initiate XCI is rather low, with estimates varying between 10 to 100 cells 25, 45 . Hence, with such a small pool of progenitor cells, it seems likely that the stochastic nature of the process plays an important role in determining the XCI-fate of the X-chromosomes present.
XCI-skewing likely is also genetically determined 46 . In mice, distortions from random-XCI are observed when several inbred mouse strains are intercrossed, and since these deviations are not caused by cell selection, they are referred to as primary non-random-XCI. This has resulted in the classification of mouse strains according to differences in strength of the X controlling element (Xce), a genetically defined locus which affects skewing 47 . 51 . Several families have been identified in which extreme XCI-skewing is inherited, but this extreme skewing could also be explained by the presence of unidentified X-linked disease alleles which are being selected against 52 when affected cells have a proliferative disadvantage, or die, as discussed above. Therefore, skewing could also be caused by X-linked mutations affecting cell viability, followed by negative selection, or sometimes even positive selection, as in the case of adrenoleukodystrophy. An even more extreme form of this secondary non-random-XCI, is found in so-called trisomic zygote rescue, and might also be causative in the development of skewing. Some cases have been described, in which placental tissues consist of a high proportion of trisomic cells, whereas the resulting fetus consist of diploid cells, which have a severely skewed XCI-phenotype 53 . It has been hypothesized that such fetuses may survive, since the initial zygote, which must have been trisomic as well, lost the supernumerary chromosomes. Since such a lucky event will only occur in a minority of cells in such an otherwise lethal embryo, even more cells might have been lost from the already small pool of cells which initiate XCI, resulting in extreme skewing observed in the girl born. Such a reduction in progenitor pool size might also underlay the observed more extreme skewing in monozygotic twins compared to singlets 54, 55 , although not all studies agree on this 45, 56 .
The selection pressure for or against cells carrying an X-linked mutation does not seem to be identical in all tissues or at all developmental stages. For example, it has been found that several X-linked diseases only result in tissue-specific skewing. In X-linked agammaglobulinemia (Bruton's agammaglobulinemia, OMIM: Table 1) , including X-linked severe combined immunodeficiency (X-SCID, OMIM: 300400) and Wiskott-Aldrich syndrome (OMIM: 301000) 58 , and extreme skewing has even been used to identify carriers of disease mutations prior to genetic testing of the disease genes 59 .
Skewing is not only influenced by tissue specificity, but also by aging. Interestingly, many studies have found that skewing is more prevalent in elderly women 60 . Certain X-linked diseases only develop in elderly women due to age-related skewing. Examples include sideroblastic anemia (OMIM: 300751) 61 and X-linked hemolytic anemia (OMIM: 305900) caused by G6PD deficiency 62 . The reason for this is unclear, but might involve stochastic clonal loss 63 , or genetic selection, potentially due to subtle, hidden mutations or SNPs affecting gene function or expression of X-linked genes, which manifest themselves gradually in growth advantage or disadvantage 64 .
What is clear from the issues discussed above is that the variability of symptoms in heterozygous female namely, due to X-linked disease the ratios between cells having inactivated the wild-type or mutant Xchromosome will differ, dependent on the effect of the mutation. However, since females have two Xchromosomes, favorable XCI-skewing, either primary or secondary due to selection, can thus often result in a better outcome of X-linked diseases compared to males, which suffer from their higher vulnerability for Xlinked diseases due to the presence of the hemizygous X-chromosome, lacking a backup allele for X-linked loci. 
WHEN MOSAICISM CAUSES A DISADVANTAGE: EMERGENCE OF MANIFESTING HETEROZYGOTES
Not always does the mosaic expression or completely skewed XCI result in a benefit for a woman. This can occur when extreme skewing results in inactivation of one X-chromosome, maybe because of selection against a mutant allele, but unfortunately also the Xa harbors a genetic defect. This disease allele, which would otherwise maybe be selected against, or the disease outcome would benefit from a mosaicism, will now be active in all cells, causing disease which is otherwise not observed in heterozygous female carriers. Such a case has been described in which a female inherited a maternal mutation in the incontinentia pigmenti gene NEMO (OMIM: 308300), and a paternal mutation in the F8 gene causing hemophilia A (OMIM: 3067000) 65 . The NEMO mutation is detrimental for cells, and thus strongly selected against, rendering all cells with the wild-type incontinentia pigmenti gene active. Unfortunately for this patient, the X-chromosome containing the wild-type NEMO gene also contains the mutant F8 gene, therefore resulting in a bleeding disorder. Table   2 ) , and some of these have even been crucial for the identification of the disease alleles involved. The reason for extreme skewing which results in the manifestation of the X-linked disease can be variable, ranging from chance to genetic causes, as discussed above. In the case of a girl presenting with Wiskott-Aldrich syndrome (OMIM: 301000) 66 , the affected girl, her mother and grandmother showed extreme skewing, pointing to a genetic cause.
Many cases of these so-called manifesting heterozygotes have been described (Supplementary
The mutant Wiskott-Aldrich syndrome was located on the Xa, causing the disease, which is normally not seen in females due to XCI of the X carrying the disease allele. Other women with Wiskott-Aldrich syndrome have been described, where XCI-skewing resulted in 100% of cells with the mutated allele on Xa 67 , or absence of skewing against the mutant allele was observed 68 . Other similar examples includes affected females with hemophilia B (OMIM: 306900), myotubular myopathy (OMIM: 310400), X-linked hemolytic anemia (OMIM: 305900), Xlinked thrombocytopenia (OMIM: 313900), ATRX syndrome (OMIM: 301040) and Fabry disease (OMIM: 301500), where also extreme XCI-skewing towards inactivation of the wild-type X-chromosome was found (Supplementary Table 2 ).
Another frequent cause of manifesting heterozygotes are X-chromosome translocations 69 . In translocations, two breaks occur, one in the X-chromosome, and another one on an autosome, after which the broken parts are joined together. Generally, either a balanced or unbalanced type of X-to-autosome translocations can be distinguished. In unbalanced X-translocations, an additional part of the X-chromosome is present, linked to a piece of autosome, representing a partial trisomy of that autosome. In general, trisomies of autosomes are not tolerated, except for partly viable trisomies of chromosome 13, 18, 21 (Patau, Edwards, and Down syndromes, respectively) which nevertheless result in severe health problems. An unbalanced X-autosome translocation will only be viable if the translocated piece of X-chromosome is able to undergo inactivation and to silence the attached piece of autosome by spreading of XCI. Therefore the translocated piece of X-chromosome must at least contain the XIC, located at Xq13. If this is not the case, this will most likely result in a non-viable situation, since cells will be confronted with a higher dosage of autosomal genes. If, in the case of an unbalanced translocation, there is no duplicated, extra part of autosome present, silencing of the translocated X-chromosome might result also in silencing of the attached autosomal segment, resulting in monosomy of autosomal genes, which is also likely to be lethal. In case of balanced translocations, the situation is different 70 . Here, the total amount of chromosome parts is the same as in a normal genome, but one piece of X-chromosome is translocated to a part of an autosome, and the other two broken parts are also joined together. Since these cells carry two Xchromosomes, XCI will be initiated. However, if inactivation is initiated on the X-autosome translocation product, this leads to silencing of autosomal genes, leading to a monosomy of the autosomal part of the fusion chromosome. Since most autosomal monosomies are incompatible with life, cells having inactivated the translocated chromosome will be selected against. Therefore, in a balanced translocation, the wild-type Xchromosome is always inactivated, leaving the translocation products active, to result in the best genetic balance.
Hence, most of the carriers of balanced translocations have a normal phenotype, although they might be sterile 70 .
However, in the process of translocation break and repair, parts of the X-chromosome might get lost, or the breakage can disrupt gene coding or regulatory sequences. Since the wild-type X-chromosome in these balanced X-to-autosome translocations is always inactivated, the disrupted gene will be on the active (parts of the) X- Table 2 ).
DISEASES WHERE FEMALES LIKELY BENEFIT FROM THEIR MOSAICISM: MALE LETHAL DISEASES AND DISEASES WITH REDUCED VIABILITY OF MALES
A severely detrimental mutation on the single X-chromosome will result in male lethality, so that no males are born carrying such a disease allele. Indeed, several X-linked disorders have been described which result in male lethality, or highly reduced male viability, and therefore these diseases are only found in females ( Table 2 ). This group of disorders is characterized by symptoms in heterozygous females, and they were originally classified as being X-linked dominant. However, symptoms amongst affected females are variable, with some patients presenting the full disease phenotypes, whereas others present as asymptomatic carriers. In most instances, XCIskewing and mosaicism are responsible for the different phenotypes observed, and explain that many affected females are alive despite carrying a disease allele which is lethal in males. Indeed, in the majority of these diseases, favorable skewing is associated with reduced symptoms. found that these genes escape XCI in humans 75 . For the latter syndrome, this might explain why human females carrying an OFD1 mutation are alive, whereas mice with a heterozygous Ofd1 knockout allele die, because Ofd1
is not escaping XCI in mouse 76 . Escape most often is incomplete and might be tissue-specific, and this might explain why XCI-skewing is still observed in some cases of these syndromes 77, 78 . A similar advantage due to escaping XCI has been proposed for the X-linked histone H3K27me3 demethylase UTX in human T-cell acute lymphoblastic leukemia, where detrimental mutations leading to leukemia were only found in male patients but not in females 79 .
X-LINKED DISEASE IN FEMALES NOT RELATED TO X-CHROMOSOME INACTIVATION OR SKEWING
As is clear from the discussion above, XCI can have a great influence on the phenotype and severity of X-linked diseases. However, not all female diseases due to X-linked mutations are necessarily influenced by XCI. Besides what is seen in manifesting heterozygotes due to unfavorable skewing, females might also experience symptoms of an X-linked disease just due to the fact that they inherited two mutant alleles for the same disease. Examples of homozygotes for X-linked diseases include females with hemophilia 80 , congenital X-linked nystagmus (OMIM: 310700) 81 , X-linked recessive ichthyosis (OMIM: 308100) 82 , hypophosphatemic rickets (OMIM: 307800) 83 and Becker muscular dystrophy (OMIM: 300376) 84 , amongst others. The chance of inheriting two Xlinked recessive alleles is low, except for genetically homogenous families or families where X-linked diseases are known to occur on both parental sides. In addition, homozygous mutations for X-linked genes can also be caused by de novo mutations 85 , or in rare causes of uniparental disomy, where both X-chromosomes present are derived from the same parent 86 . Also, manifestations of X-linked diseases in females sometimes discover a hidden, or not yet diagnosed form of Turner syndrome, in which a female has only one X-chromosome, thus rendering a Turner female prone to the same risk of developing an X-linked disease as a hemizygous male 87, 88 .
Even more rarely, the presence of an X-linked disease has discovered cases of dysregulated sex-determination, where affected females turned out to have a male karyotype 89, 90 .
The benefits or disadvantages of mosaicism related to X-linked gene expression may not always be related to XCI. For example, rare cases of mosaicism may be caused by fusion of two distinct zygotes, or due to placental transport of cells between twins 91 . Such chimaeras might display mosaicism, in which one population of cells harbors an X-linked mutation, whereas the other carries a wild-type allele. Also mutations occurring during postzygotic stages of development will result in the fact that not all cells of the body will harbor a mutation. The later in embryonic development the mutation occurs, the fewer cells will be affected 92 . In such cases, it is also possible that the mutation does not affect the germ line, which is important for counseling issues and the risk of transmitting the disorder to the offspring
CONCLUSION AND OUTLOOK
It has become clear in recent years that XCI is not only a fascinating biological process occurring during early female embryonic development, but also an important modifier of X-linked disease in females. The accompanying online-only discussion further elaborates on this, by providing an extensive review of hematological, immunological, neurological, muscle, metabolic, renal, dermatological, and ocular diseases affected by XCI, and the influence of this process on cancer, pregnancy loss and structural and numerical disorders of the X-chromosome. Whereas the ancient opinion that X-linked disease is only relevant for males has become a subject of change, which is emphasized by the large number of reports linking XCI-skewing to the phenotypes in females discussed in this review, in the next step it will be crucial to link the fundamental knowledge obtained by basic research on the regulation of XCI-initiation to future clinical implications. For example, it is highly likely that currently non-understood effects of XCI-initiation in females explain why relatively fewer females are born compared to males. In all Western civilizations, at present the birth ratio is around male: female = 1.05:1.0, as exemplified for the Netherlands (Supplementary Figure 1) . Whereas at the moment of fertilization, an equal ratio between both sexes is found 93 , and during recognized pregnancy and during postnatal development more males are dying (most likely reflecting the male disadvantage due to the hemizygous X-chromosome) 94 , apparently a large number of female embryos is lost around the time of implantation in the uterus 95 . It is that around that time, the only significant difference known between both sexes is the XCI-process, and hence it is likely that effects of this process, as they might for example occur due to stochastic XCI-initiation on too many or less X-chromosomes as observed in differentiating mouse ES cells and embryos, are contributing to this observation. Our fundamental insights in XCI might help to develop targeted X-reactivation methods, which could be used to treat heterozygous females suffering from X-linked disease due to preferential inactivation of the wild-type X-chromosome (Figure 3) . Some first successes have been obtained by applying such ideology to the treatment of Rett syndrome 96, 97 , and recent efforts to reactivate the X chromosome are promising 98 , although this strategy should also be taken with caution as this could have adverse effects as well 99 . Nevertheless, we foresee that important new breakthroughs, such as targeted X-reactivation, will follow in the near future, bridging the gap between fundamental XCI-research and the clinic. A) The X-inactivation center in mouse contains the non-coding gene Xist and its antisense partner Tsix.
Figure Legends
Transcription trough the Tsix locus can inhibit Xist expression, and Xist RNA, when upregulated, can coat the future inactive X-chromosome and recruits chromatin modifying enzymes, which results in gene silencing. Both genes are regulated by trans-acting autosomally-encoded XCI-inhibitors and Xlinked XCI-activators, and a cis-acting landscape, which together ensure female specific initiation of the important X-chromosome inactivation process.
B) The homologous X-inactivation center in human , only the allele which is inactivated, and hence methylated, will be amplified. Therefore in males, upon digestion, no band is detectable. When X-chromosome inactivation is random in females, 50% of cells will methylate the one allele, whereas 50% of cells will methylate the second allele. Therefore, in a non-skewed female, the same bands will be seen upon digestion as in the undigested sample (middle panel). Upon complete skewing (right panel), only a single allele will be detected.
Figure 3:
X chromosome reactivation as a potential novel treatment for X-linked disorders in females. When a wild-type X chromosome which is silenced could get reactivated, a cell will re-express a wild-type copy of the missing or non-functioning protein, which might result in an improvement of the disease phenotype. 
